Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Harvard Business School
Baxter
Medtronic
Express Scripts

Last Updated: November 17, 2019

DrugPatentWatch Database Preview

TRIZIVIR Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Trizivir, and when can generic versions of Trizivir launch?

Trizivir is a drug marketed by Viiv Hlthcare and is included in one NDA.

The generic ingredient in TRIZIVIR is abacavir sulfate; lamivudine; zidovudine. There are twelve drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.

Drug patent expirations by year for TRIZIVIR
Drug Prices for TRIZIVIR

See drug prices for TRIZIVIR

Recent Clinical Trials for TRIZIVIR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Institute of Allergy and Infectious Diseases (NIAID)Phase 3
AIDS Clinical Trials GroupPhase 3
Ines PerezPhase 4

See all TRIZIVIR clinical trials

Recent Litigation for TRIZIVIR

Identify potential future generic entrants

District Court Litigation
Case NameDate
ViiV Healthcare UK Ltd. v. Lupin Ltd.2011-06-29
Glaxo Group Ltd. v. Lupin Ltd.2008-08-29

See all TRIZIVIR litigation

PTAB Litigation
PetitionerDate
Teva Pharmaceuticals USA, Inc.2015-01-08
Apotex Corp.2014-06-02

See all TRIZIVIR litigation

Paragraph IV (Patent) Challenges for TRIZIVIR
Tradename Dosage Ingredient NDA Submissiondate
TRIZIVIR TABLET;ORAL abacavir sulfate; lamivudine; zidovudine 021205 2011-03-22

US Patents and Regulatory Information for TRIZIVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare TRIZIVIR abacavir sulfate; lamivudine; zidovudine TABLET;ORAL 021205-001 Nov 14, 2000 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for TRIZIVIR

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
Moodys
Merck
Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.